Chemosensitivity During Phases of the Menstrual Cycle in Breast Cancer Patients
This study is a prospective, multicenter study in which a serum sample will be collected at the day of starting neo adjuvant treatment in breast cancer patients
Breast Cancer
PROCEDURE: Blood sample
pCR rate, Number of patients achieving a pathological complete response, At 6 months
Radiological reduction on tumor size, Number of patients achieving a radiological response (CR, PR, SD) based on MRI after neo adjuvant treatment, At 6 months|Pathological reduction on tumor size, Number of patients achieving a pathological response (CR, PR, SD) based on pathology report after neo adjuvant, At 6 months|Residual cancer burden (RCB), quantificaton of the residual disease after neoadjuvant therapy, At 6 months|Distant recurrence free interval (DRFI), Number of patients with distant recurrence, Up to 120 months|Recurrence-free interval (RFI), Number of patients with disease recurrence, Up to 120 months|Overall survival (OS), Number of patients alive or deceased, Up to 120 months
This study is a prospective, multicenter study in which a serum sample will be collected at the day of starting neo adjuvant treatment in breast cancer patients